LGC Capital Completes Acquisition of Initial Strategic Interest in Licenced Australian Medical Cannabis Company – Little Green Pharma

MONTREALOct. 12, 2017 – LGC Capital Ltd. (TSXV: LG) (“LGC”) is pleased to announce that it has today completed the acquisition of stage one of its strategic interest in licenced Australian Medical Cannabis company Habi Pharma Pty Ltd of Perth, Australia, doing business as “Little Green Pharma”, as announced on September 26, 2017 and October 5, 2017. On October 5, 2017, the Company announced that the TSX Venture Exchange had authorized LGC to proceed to the closing of the transaction and this transaction has now been completed.

At the closing, LGC subscribed for 2,161,091 shares of Little Green Pharma, representing an initial 4.99% of its issued and outstanding shares. As consideration for the shares, LGC paid AUD $432,218 and issued 5,660,000 LGC common shares to Little Green Pharma at a deemed issue price of $0.11 per share. LGC, subject to certain Australian regulatory and other approvals, can now move towards increasing its interest in Little Green Pharma up to 19.03%.

About Little Green Pharma:

Little Green Pharma is one of the few companies in Australia to be granted a licence to cultivate and produce Medical Cannabis within Australia.

Little Green Pharma (www.lgpharma.com.au) has advised LGC that it plans to commence cultivation and production of one of the first clean locally-grown Medical Cannabis products for use solely within Australia, giving hope and relief to those suffering from certain debilitating illnesses. Little Green Pharma’s patented technology aims to control the medicinal cannabis particle size encapsulated in the liposomes to optimise the bio-availability so the cannabinoids are readily absorbed into the bloodstream. This enables the resulting preparation to achieve desired therapeutic results with significantly lower cannabinoid doses, when compared to other forms of medicinal cannabis. Little Green Pharma’s patented process significantly reduces production costs, enabling Little Green Pharma to be more competitive in the market.

The Australian Medical Cannabis Market:

Little Green Pharma has advised LGC that Australia passed federal legislation in 2016 aimed at permitting the use of Medicinal Cannabis via a tightly-controlled licensed medical prescription system.

In March 2016The White Paper, entitled Medicinal Cannabis in Australia: Science, Regulation & Industry, was developed by the University of Sydney Business School’s Community Placement Program. Its publication followed the news that the Australian Government would shortly allow the cultivation of cannabis in Australia for medical or scientific purposes.

As the first-ever White Paper that analyses the medicinal cannabis industry in Australia, the paper examines international experiences and approaches, supply chain economics, quantities of cannabis required and potential regulatory dynamics. It also serves as a framework for the industry to commence engaging key stakeholders such as the Australian Government and the medical community.

The University of Sydney summary of the White Paper can be viewed via the below link:

http://sydney.edu.au/news-opinion/news/2016/03/29/legalising-medicinal-cannabis-would-create–100-million-industry.html

The White paper can be viewed at:

http://mgcpharma.com.au/wp-content/uploads/2016/03/mgc_whitepaper_final-sml.pdf

Highlights of the White Paper:

  • Australia would need to produce 8,000 kg of medicinal cannabis per year to service the existing market.
  • Australian market currently estimated to be worth AUD $100 million to AUD $150 million per annum, and is likely to grow significantly in the next decade.
  • Medical Cannabis has the potential to help tens of thousands of patients suffering from a wide range of medical conditions such as Multiple Sclerosis, Epilepsy, Cancer, and Severe and Chronic Pain.
  • Up to 51,000 square metres of greenhouse space – almost three times the size of the Sydney Cricket Ground – would be needed to produce the amount of cannabis required to meet demand.

Further investment stages of the Little Green Pharma acquisition:

As previously announced, the subscription agreement between LGC and Little Green Pharma provides that subject to the issuance by Little Green Pharma of shares to various third parties, LGC will subscribe for a further 752,937 shares of Little Green Pharma for cash consideration of AUD $150,587, so as to maintain its shareholding in Little Green Pharma of 4.99%. In addition, subject to certain Australian regulatory approvals, which are currently in progress, and subject to approval by Little Green Pharma in its sole discretion, LGC may further subscribe, at its option, for additional shares of Little Green Pharma in order to increase its shareholding to a maximum of 19.03%. In the event that this option is exercised, LGC will subscribe for a maximum of 4,585,972 shares of Little Green Pharma for maximum cash consideration of AUD $917,194.

Note: On October 11, 2017, the Bank of Canada’s daily average exchange rate for the Australian dollar was AUD $1.00 = CAD $0.9728.

About LGC (http://www.lgc-capital.com)

LGC Capital Ltd.’s (TSXV: LG) mission is to invest into global high-yield diversified businesses. LGC’s flagship project is its partnership with AfriAg (Pty) Ltd. and South Africa’s House of Hemp to grow, cultivate and distribute medical-grade cannabis from its 40,000 m2 facility located in Block D of the Dube Tradeport’s Agrizone Complex. This greenhouse is the most eco-friendly and high tech agricultural facility in Africa.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640

Investor Relations contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its investment in Little Green Pharma, and LGC’s operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, including its proposed investment in Little Green Pharma, could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.

Information Relating to Little Green Pharma:
All information contained in this press release relating to Little Green Pharma has been provided to LGC by Little Green Pharma. LGC has relied upon this information without having made independent inquiries as to its accuracy or completeness and assumes no responsibility for any inaccuracy or incompleteness of such information.

Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

LGC Capital Signs Definitive Agreement to Acquire Strategic Interest in Licenced Australian Medical Cannabis Company – Little Green Pharma

TSX Venture Exchange authorizes LGC to proceed to closing of the transaction, scheduled for Tuesday, October 10, 2017

MONTREALOct. 5, 2017 – LGC Capital Ltd. (TSXV: LG) (“LGC”) is pleased to announce that it has entered into a definitive Subscription Agreement with licenced Australian Medical Cannabis company Habi Pharma Pty Ltd of Perth, Australia, doing business as “Little Green Pharma”, for the acquisition of a strategic interest in Little Green Pharma, as announced on September 26, 2017. LGC is also pleased to announce that the TSX Venture Exchange has authorized LGC to proceed to the closing of the transaction, which is scheduled to take place on Tuesday, October 10, 2017.

Little Green Pharma is one of the few licenced companies in Australiaauthorized to cultivate and produce Medical Cannabis within Australia.

Little Green Pharma (www.lgpharma.com.au) has advised LGC that it plans to commence cultivation and production of one of the first clean locally-grown Medical Cannabis products for use solely within Australia, giving hope and relief to those suffering from certain debilitating illnesses. Little Green Pharma’s patented technology aims to control the medicinal cannabis particle size encapsulated in the liposomes to optimise the bio-availability so the cannabinoids are readily absorbed into the bloodstream. This enables the resulting preparation to achieve desired therapeutic results with significantly lower cannabinoid doses, when compared to other forms of medicinal cannabis. Little Green Pharma’s patented process significantly reduces production costs, enabling Little Green Pharma to be more competitive in the market.

“The signing of a definitive Subscription Agreement and approval by the TSX Venture Exchange to acquire this strategic initial interest in Little Green Pharma in Australia are truly landmarks for LGC Capital, as we seek to expand the Company’s global footprint in the fast-growing legalized medical cannabis industry” John McMullen, LGC’s CEO commented. “We are pleased to be given the opportunity to be a key strategic shareholder of Little Green Pharma as it moves towards commercial production in the highly regulated and blue-chip Australian market. We are also very excited about Little Green Pharma’s advanced patented technology.”

Fleta Solomon, Little Green Pharma’s Managing Director, commented; “There is no doubt that LGC Capital is going to be a strong strategic partner as we expand the company and its opportunities.”

The details of LGC’s agreement to invest in Little Green Pharma are as follows:

  1. At closing, LGC will subscribe for 2,161,091 shares of Little Green Pharma, representing an initial 4.99% of its issued and outstanding shares, by paying AUD $432,218 and issuing 5,660,000 LGC common shares to Little Green Pharma at a deemed issue price of $0.11 per share.
  2. Subject to the issuance by Little Green Pharma of shares to various third parties, LGC will subscribe for a further 752,937 shares of Little Green Pharma for cash consideration of AUD $150,587, so as to maintain its shareholding of 4.99% in Little Green Pharma.
  3. Subject to certain Australian regulatory approvals, which are currently in progress, and subject to approval by Little Green Pharma in its sole discretion, LGC may further subscribe, at its option, for additional shares of Little Green Pharma in order to increase its shareholding to a maximum of 19.03%. In the event that this option is exercised, LGC will subscribe for a maximum of 4,585,972 shares of Little Green Pharma for maximum cash consideration of AUD $917,194.

Note: On October 4, 2017, the Bank of Canada’s daily average exchange rate for the Australian dollar was AUD $1.00 = CAD $0.9802.

Closing of the transaction with Little Green Pharma is subject to standard conditions.


About LGC (http://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

Investor Relations contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640;

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, including any investment in the Medical Cannabis sector, could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.

Information Relating to Little Green Pharma
All information contained in this news release relating to Little Green Pharma has been provided to LGC by Little Green Pharma. LGC has relied upon this information without having made independent inquiries as to its accuracy or completeness and assumes no responsibility for any inaccuracy or incompleteness of such information.

Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

LGC Capital Signs Binding Term Sheet to Acquire Strategic Interest in Licenced Australian Medical Cannabis Company – Little Green Pharma

MONTREALSept. 26, 2017 – LGC Capital Ltd. (TSXV: LG) (“LGC”) announces that it has entered into a binding term sheet with Habi Pharma Pty Ltd of Perth, Australia, doing business as “Little Green Pharma“, which provides that LGC will acquire an initial strategic 4.99% interest in Little Green Pharma, one of the few licenced companies authorized to cultivate and produce Medical Cannabis within Australia. The binding term sheet provides that LGC has the option to increase its interest in Little Green Pharma to a maximum of 19.03%, subject to a number of conditions, including Australian Government regulatory approvals.

Little Green Pharma (www.lgpharma.com.au) has advised LGC that it plans to commence cultivation and production of one of the first clean locally-grown Medical Cannabis products for use solely within Australia, giving hope and relief to those suffering from certain debilitating illnesses.

John McMullen, LGC’s CEO, commented; “This will be LGC’s first investment into the legalized Medical Cannabis sector in the Asia-Pacific region. This will be an important investment initiative for LGC in the region as Little Green Pharma is one of the few companies in Australia licenced to cultivate and produce Medical Cannabis. Australiahas now legalized the use of Medical Cannabis and Little Green Pharma plans to commence production shortly.”

Fleta Solomon, Little Green Pharma’s Managing Director, commented; “We look forward to having LGC on board as a new strategic long-term shareholder in Little Green Pharma. LGC’s support and funding will assist in providing the necessary working capital to allow Little Green Pharma to cultivate and produce our product range for Australian patients in the coming months.”

Binding Term Sheet

The binding term sheet between LGC and Little Green Pharma provides that:

  1. LGC will subscribe for 2,161,091 shares of Little Green Pharma, representing 4.99% of its issued and outstanding shares, by paying AUD $432,218 and issuing 5,660,000 LGC common shares to Little Green Pharma at a deemed issue price of $0.11 per share.
  2. Subject to the issuance by Little Green Pharma of shares to various third parties, LGC will subscribe for a further 752,937 shares of Little Green Pharma for cash consideration of AUD $150,587, so as to maintain its shareholding of 4.99% in Little Green Pharma.
  3. Subject to approval by Little Green Pharma in its sole discretion, LGC may further subscribe, at its option, for additional shares of Little Green Pharma in order to increase its shareholding to a maximum of 19.03%.  In the event that this option is exercised, LGC will subscribe for a maximum of 4,585,972 shares of Little Green Pharma for maximum cash consideration of AUD $917,194.

On September 25, 2017, the Bank of Canada’s daily average exchange rate for the Australian dollar was AUD $1.00 = CAD $0.9806.

Closing Conditions

Closing of the transaction with Little Green Pharma is subject to standard conditions, including the negotiation and signing of a definitive subscription agreement between LGC and Little Green Pharma. LGC cannot give any assurance that the transaction with Little Green Pharma will close in accordance with the terms and conditions of the binding term sheet or at all. Further, LGC cannot proceed with any investment in Little Green Pharma prior to obtaining formal approval from the TSX Venture Exchange with respect thereto. Although LGC has commenced the process for obtaining formal approval from the TSX Venture Exchange, LGC cannot give any assurance that it will be able to obtain such approval.

LGC will require the approval of the Australian Government’s Office of Drug Control (ODC) in order to increase its interest in Little Green Pharma to more than 4.99% and may require the approval of the Australian Foreign Investment Review Board (FIRB) to increase its interest in Little Green Pharma to more than 15%. Little Green Pharma has agreed to provide all necessary assistance and support to LGC with respect to such government approvals. LGC cannot give any assurance that it will be able to obtain such approvals, to the extent necessary.

Little Green Pharma

LGC understands that Little Green Parma is a privately-owned company based in Western Australia and that in April 2017, Little Green Pharma was granted one of the few licenses in Australia by the Australian Government’s Office of Drug Control (ODC) to cultivate and produce Medicinal Cannabis for Australian patients from June 1, 2017.

Little Green Pharma has stated that its goal is to make safe, reliable and cost-effective Medicinal Cannabis products available to Australians through approved medical practitioners, and that it will produce a range of Medical Cannabis preparations with differing cannabinoid profiles from multiple plant varieties.
Little Green Pharma has advised LGC that it has an advanced manufacturing technology for producing Medicinal Cannabis for oral administration. Its process ensures high bio-availability of the active cannabinoids, meaning that a therapeutic effect can be achieved with precise dosage control and with significantly lower cannabinoid doses.

Little Green Pharma has stated that its manufacturing process can maintain the integrity of CBD-A and THC-A if required, avoiding the carboxylation of important cannabinoids. Preparations will meet strict regulatory standards for medicinal cannabis specifications ensuring a clean, high-quality product. All growing, production and good manufacturing practice is subject to the terms of the Australian federal licence aimed at security and quality assurance by the relevant regulatory bodies.

The Australian Medical Cannabis Market

Little Green Pharma has advised LGC that Australia passed federal legislation in 2016 aimed at permitting the use of Medicinal Cannabis via a tightly-controlled licensed medical prescription system.

In March 2016The White Paper, entitled Medicinal Cannabis in Australia: Science, Regulation & Industry, was developed by the University of Sydney Business School’s Community Placement Program. Its publication followed the news that the Australian Government would shortly allow the cultivation of cannabis in Australia for medical or scientific purposes.

As the first-ever White Paper that analyses the medicinal cannabis industry in Australia, the paper examines international experiences and approaches, supply chain economics, quantities of cannabis required and potential regulatory dynamics. It also serves as a framework for the industry to commence engaging key stakeholders such as the Australian Government and the medical community.

The University of Sydney summary of the White Paper can be viewed via the below link:

http://sydney.edu.au/news-opinion/news/2016/03/29/legalising-medicinal-cannabis-would-create–100-million-industry.html

The White paper can be viewed at:

http://mgcpharma.com.au/wp-content/uploads/2016/03/mgc_whitepaper_final-sml.pdf

Highlights of the White Paper:

  • Australia would need to produce 8,000 kg of medicinal cannabis per year to service the existing market.
  • Australian market currently estimated to be worth AUD $100 million –AUD $150 million per annum, and is likely to grow significantly in the next decade.
  • Medical Cannabis has the potential to help tens of thousands of patients suffering from a wide range of medical conditions such as Multiple Sclerosis, Epilepsy, Cancer, and Severe and Chronic Pain.
  • Up to 51,000 square metres of greenhouse space – almost three times the size of the Sydney Cricket Ground – would be needed to produce the amount of cannabis required to meet demand.

About LGC (http://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

Investor Relations contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640;

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, including any investment in the Medical Cannabis sector, could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.

Information Relating to Little Green Pharma
All information contained in this news release relating to Little Green Pharma has been provided to LGC by Little Green Pharma. LGC has relied upon this information without having made independent inquiries as to its accuracy or completeness and assumes no responsibility for any inaccuracy or incompleteness of such information.

Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

LGC Capital Ltd. Exits All Investment Activity Associated With Cuba To Focus On Its Global Medical Cannabis Initiatives And Other Investment Opportunities

Montreal, Québec – September 26, 2017 – LGC Capital Ltd. (TSXV: LG) (“LGC”) announces that its Board of Directors has resolved to immediately exit all current investments, partnerships and joint venture arrangements with companies or entities that have any business activities relating to Cuba.

While LGC continues to be positive towards the investment opportunities in Cuba, regrettably the U.S. government embargo on Cuba places onerous restrictions on LGC’s critical ability to transact with key banking and financial market institutions. These restrictions have also severely limited LGC’s ability to broaden its investor and shareholder base.

LGC’s focus has changed considerably since its initial investment in the legalized Medical Cannabis sector in June 2017. LGC will now continue with its growth strategy of increasing its investment footprint in this fast-growing and globally-expanding sector, with the exception of investments in businesses operating in the United States.

LGC will also review new investment opportunities in other sectors that the Board considers may add value for shareholders. These new investments will not carry the burden of limitations and restrictions from the financial community as Cuban investments and businesses currently do.

John McMullen, LGC’s CEO, commented:

It’s now time to open up LGC to the wider investment and banking community outside of Canada by completely exiting our business initiatives and joint ventures in Cuba.

“This move, although regrettable, should enable LGC to broaden its shareholder base and establish corporate advisory and banking relationships in jurisdictions that previously would not deal with LGC due to restrictions placed on these organizations by the U.S. government. This corporate decision should, for the first time, open up LGC to potential U.S. investors. We will now actively engage with our advisors in Canada to notify international brokerage firms, banks and share-clearing agencies of our decision to exit Cuba.

“LGC still sees tremendous investment opportunities in Cuba, but will no longer invest in any company that has activities in Cuba”, Mr. McMullen concluded.

LGC cannot proceed with any investment in a business or operation related to the Medical Cannabis industry prior to obtaining formal approval from the TSX Venture Exchange with respect thereto.

About LGC (http://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: LG). LGC’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

Investor Relations contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640;

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, including any investment in the Medical Cannabis sector, could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.

Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

LGC Capital Ltd. Updates Corporate Presentation

MONTREALSept. 19, 2017  – LGC Capital Ltd. (TSXV: LG)(“LGC“) announces that it has updated its Corporate Presentation, which is available on LGC’s web site (www.lgc-capital.com), as well as certain information on the web site to reflect the changing nature of its businesses and investments.

The Corporate Presentation and web site, as updated, specify that LGC’s joint venture to grow and distribute medical and recreational cannabis products in South Africa is with AfriAg (Pty) Ltd., which is 40% owned by AfriAg Global plc, a company listed on the fully-regulated NEX Growth Market in London. They also specify that LGC and its joint venture partner AfriAg (Pty) Ltd. signed an agreement with South Africa’s House of Hemp (http://houseofhemp.co.za) under which the joint venture has the sole and exclusive right to acquire a 60% economic and beneficial interest in House of Hemp, as announced on June 26, 2017.

The Corporate Presentation and web site, as updated, are consistent with LGC’s press releases issued on June 26, 2017 and July 18, 2017, respectively, both of which are available under LGC’s profile on SEDAR at www.sedar.com and via LGC’s web site. LGC has made certain other conforming changes to the Corporate Presentation.

Mr. David Lenigas, who is Co-Chairman and a director of LGC, is also Executive Chairman of AfriAg Global plc and a director of AfriAg (Pty) Ltd.

About LGC (http://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital has now entered into the agricultural space and the medical cannabis sector in southern Africa through its new joint venture with AfriAg and is seeking new investments opportunities in this sector not only in southern Africa but also elsewhere in the world.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

Investor Relations contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640;

Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital Ltd. announces Director resignation

MONTREALSept. 18, 2017  – LGC Capital Ltd. (TSXV: QBA) (“LGC“) announces the resignation of Mr. Sébastien Bellefleur as a Director of the Corporation effective September 13, 2017. The Board of Directors wishes to thank Mr. Bellefleur for his contribution to LGC Capital and wishes him every success in his future endeavours.  The Corporation will initiate a search for a new director to replace Mr. Bellefleur.

About LGC (http://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital has now entered into the agricultural space and the medical cannabis sector in southern Africa through its new joint venture with AfriAg and is seeking new investments opportunities in this sector not only in southern Africa but also elsewhere in the world.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

Investor Relations contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640;

Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital Ltd. to change stock symbol to “LG”

MONTREAL, Sept. 14, 2017 – LGC Capital Ltd. (TSXV: QBA) (“LGC“) announces that its stock symbol will change to “LG” effective at the opening of the markets on Monday, September 18, 2017.  Until that time, LGC’s shares will continue to trade under the current stock symbol “QBA”.  LGC’s shares are listed on the TSX Venture Exchange.

About LGC (http://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital has now entered into the agricultural space and the medical cannabis sector in southern Africa through its new joint venture with AfriAg and is seeking new investments opportunities in this sector not only in southern Africa but also elsewhere in the world.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

Investor Relations contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640;

Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital Ltd. Raises $2,630,616 at First Closing of Private Placement

MONTREAL, Sept.11, 2017 – LGC Capital Ltd. (TSXV: QBA) (“LGC”) is pleased to announce that it has raised gross proceeds of $2,630,616 at a first closing of its previously-announced private placement by issuing 26,306,160 units at a price of $0.10 per unit. LGC expects to hold a final closing for the balance of 3,693,840 units ($369,384) by Wednesday, September 13, which will bring the total amount raised in the private placement to the previously-announced maximum of $3 million. The units were sold to “accredited investors” in Canada and internationally; LGC’s senior management and directors subscribed for an aggregate of 3,355,900 units ($335,590).

Each of the units is comprised of one common share and one common share purchase warrant; each warrant entitles its holder to acquire one additional LGC common share at a price of $0.15 for a period of one year from the closing date. In the event that the closing price of LGC’s common shares on the TSX Venture Exchange is at least $0.20 for a period of not less than 20 consecutive trading days, the warrants will expire, at the sole discretion of LGC, on the 30th day after the date on which LGC sends a notice in prescribed form to the holders of the warrants.

As previously announced, LGC will use the net proceeds from the private placement to assist with the funding of LGC’s new joint venture with AfriAg (Pty) Ltd and the investment by the joint venture in the House of Hemp (Pty) Ltd in South Africa. The net proceeds may also be used for new medical cannabis investment opportunities elsewhere in southern Africa and in the Asia Pacific Region.

At the first closing, LGC paid cash commissions to various securities dealers in an aggregate amount of $93,200, representing 8% of the proceeds from the sale of units sold through such dealers. In addition, LGC issued an aggregate of 932,000 “broker warrants” to such dealers, representing an amount equal to 8% of the number of units sold through them. Each of the broker warrants will entitle the holder to purchase one additional LGC common share at a price of $0.10 for a period of six months from the closing date of the private placement.

The securities issued at the first closing are subject to a “hold period” which expires on January 12, 2018.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, and these securities will not be offered or sold in any jurisdiction in which their offer or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws of the United States.  Accordingly, these securities will not be offered or sold to persons within the United States unless an exemption from the registration requirements of the 1933 Act and applicable state securities laws is available.

About LGC (http://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital has now entered into the agricultural space and the medical cannabis sector in southern Africa through its new joint venture with AfriAg and is seeking new investments opportunities in this sector not only in southern Africa but also elsewhere in the world.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640;

Investor Relations contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

FORWARD LOOKING STATEMENTS

This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its Joint Venture with AfriAg, its investment in House of Hemp, and LGC’s operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, the Joint Venture with AfriAg and the investment in House of Hemp could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, changes in government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC, the Joint Venture, and persons acting on their respective behalves. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.

Caution Regarding Press Releases

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital to Issue Shares in Payment of Two Debts

MONTREALSept, 5, 2017  – LGC Capital Ltd. (TSXV: QBA) (“LGC”) announces that it has reached an agreement to issue an aggregate of 1,230,468 common shares in settlement of two debts in an aggregate amount of $124,585 (the “Debt Settlement”).  The debts are with, respectively, an insider of LGC and a company for which such insider serves as Finance Director and Corporate Secretary.

The Board of Directors and Management of LGC Capital believe that the Debt Settlement is in the best interests of LGC as it will help LGC preserve its cash position. The common shares to be issued pursuant to the Debt Settlement will be issued at a deemed price of $0.10125 per share and will be subject to a four-month hold period pursuant to applicable securities regulations and the policies of the TSX Venture Exchange.

The Debt Settlement is considered a “related party transaction” as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Debt Settlement will be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as LGC’s securities are not listed on any stock exchange identified in Section 5.5(b) of MI 61-101 and neither the fair market value of the common shares to be issued in the Debt Settlement nor of the services provided in connection with the two debts which are the subject of the Debt Settlement exceeds 25% of LGC’s market capitalization.

The Debt Settlement is subject to regulatory approval, including that of the TSX Venture Exchange.

About LGC (http://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital has now entered into the agricultural space and the medical cannabis sector in southern Africa through its new joint venture with AfriAg and is seeking new investments opportunities in this sector not only in southern Africa but also elsewhere in the world.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

Or for Investor Relations please contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

FORWARD LOOKING STATEMENTS

This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its Joint Venture with AfriAg, its investment in House of Hemp, and LGC’s operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, the Joint Venture with AfriAg and the investment in House of Hemp could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, changes in government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC, the Joint Venture, and persons acting on their respective behalves. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.

Caution Regarding Press Releases

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital Raises $3 Million to Fund Global Medical Cannabis Expansion Plans

MONTREAL, September 5, 2017 – LGC Capital Ltd. (TSXV: QBA) (“LGC” or “LGC Capital) is pleased to announce that the subscription agreements received to date totals $3.0 million for its private placement of a maximum of 30,000,000 units, which has conditional approval from the TSX Venture Exchange, at a price of $0.10 per unit, for maximum gross proceeds to LGC of $3.0 million.

LGC has now received additional signed subscription agreements and subscription funds for a total aggregate amount of $3,000,000, which represents 30,000,000 units, of which senior management and directors are contributing $477,636. Due to the long weekend LGC announces that the TSX Venture Exchange has set Friday, September 8, 2017 as the deadline for closing of the private placement.

John McMullen, LGC’s CEO, comments:

“On behalf of LGC I would like to personally thank our new investors and the company’s insiders for investing in LGC’s global strategy. This money will rapidly advance our legal medical cannabis initiatives not only in southern Africa but will and also the Company to pursue new investment initiatives in the Asian Pacific region where we see accretive legal cannabis opportunities.”

Each of the units will be comprised of one common share and one common share purchase warrant; each warrant will entitle its holder to acquire one additional LGC common share at a price of $0.15 for a period of one year from the closing date. In the event that the closing price of LGC’s common shares on the TSX Venture Exchange is at least $0.20 for a period of not less than 20 consecutive trading days, the warrants will expire, at the sole discretion of LGC, on the 30th day after the date on which LGC sends a notice in prescribed form to the holders of the warrants.

The units are being offered to “accredited investors” in some or all of the provinces of Canada and in other global jurisdictions, if any, determined by LGC.

At the closing of the private placement, LGC will pay cash commissions to various securities dealers in an amount equal to 8% of the proceeds from the sale of units sold through such dealers. In addition, LGC will issue “broker warrants” to such dealers in an amount equal to 8% of the number of units sold through them. Each of the broker warrants will entitle the holder to purchase one additional LGC common share at a price of $0.10 for a period of six months from the closing date of the private placement.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, and these securities will not be offered or sold in any jurisdiction in which their offer or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws of the United States. Accordingly, these securities will not be offered or sold to persons within the United States unless an exemption from the registration requirements of the 1933 Act and applicable state securities laws is available.

About LGC (http://www.lgc-capital.com)

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital has now entered into the agricultural space and the medical cannabis sector in southern Africa through its new joint venture with AfriAg and is seeking new investments opportunities in this sector not only in southern Africa but also elsewhere in the world.

For further information please contact:

LGC Capital:
John McMullen, Chief Executive Officer
Tel: +1(416) 803-0698
Email: John@lgc-capital.com

Or for Investor Relations please contact:
The Howard Group Inc.
Dave Burwell, Vice President
Tel: +1(403) 221-9015
Toll Free in Canada: 1-888-221-0915,
Email: dave@howardgroupinc.com

FORWARD LOOKING STATEMENTS

This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its Joint Venture with AfriAg, its investment in House of Hemp, and LGC’s operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, the Joint Venture with AfriAg and the investment in House of Hemp could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, changes in government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC, the Joint Venture, and persons acting on their respective behalves. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.

Caution Regarding Press Releases

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital Increases Capital Raise to $2.4 Million to Fund Medical Cannabis Expansion Plans

MONTREAL, Aug. 24, 2017 – LGC Capital Ltd. (TSXV: QBA)(“LGC or “LGC Capital“) is pleased to advise that the Company has now received additional signed subscription agreements and subscription funds increasing the aggregate total amount raised to $2,410,000, which represents 24,100,000 units. Of that amount, senior management is contributing $300,000.

LGC has conditional approval from the TSX Venture Exchange for a private placement of a maximum of 30,000,000 units at a price of $0.10per unit, for maximum gross proceeds to LGC of $3.0 million. The Exchange has set the closing date to be on or before September 1, 2017.

John McMullen, CEO of LGC Capital comments;

“On behalf of LGC we would like to thank those who have invested into the Company and recognize the potential of our new global medical cannabis initiatives.  Our partners at AfriAg and House of Hemp are working tirelessly to advance our existing opportunities in South Africa. As stated previously, a proportion of this new funding will also be channeled towards seeking new medical cannabis investment opportunities elsewhere in southern Africa and in the Asia Pacific Region.”

Each of the units will be comprised of one common share and one common share purchase warrant; each warrant will entitle its holder to acquire one additional LGC common share at a price of $0.15 for a period of one year from the closing date. In the event that the closing price of LGC’s common shares on the TSX Venture Exchange is at least $0.20 for a period of not less than 20 consecutive trading days, the warrants will expire, at the sole discretion of LGC, on the 30th day after the date on which LGC sends a notice in prescribed form to the holders of the warrants.

The units are being offered to “accredited investors” in some or all of the provinces of Canada and in other jurisdictions, if any, determined by LGC.

At the closing of the private placement, LGC will pay cash commissions to various securities dealers in an amount equal to 8% of the proceeds from the sale of units sold through such dealers. In addition, LGC will issue “broker warrants” to such dealers in an amount equal to 8% of the number of units sold through them. Each of the broker warrants will entitle the holder to purchase one additional LGC common share at a price of $0.10 for a period of six months from the closing date of the private placement.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, and these securities will not be offered or sold in any jurisdiction in which their offer or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws of the United States. Accordingly, these securities will not be offered or sold to persons within the United States unless an exemption from the registration requirements of the 1933 Act and applicable state securities laws is available.

About LGC (http://www.lgc-capital.com)
LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital has now entered into the agricultural space and the medical cannabis sector in southern Africa through its new joint venture with AfriAg and is seeking new investments opportunities in this sector.


For further information please contact:

Canada contact:
John McMullen, Chief Executive Officer
Tel.: (416) 803-0698
Email: John@lgc-capital.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640

Investor Relations
Dave Burwell
The Howard Group Inc.
Tel.: (403) 221-9015
Toll Free: 1-888-221-0915
Email: dave@howardgroupinc.com

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its Joint Venture with AfriAg, its investment in House of Hemp, and LGC’s operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, the Joint Venture with AfriAg and the investment in House of Hemp could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, changes in government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC, the Joint Venture, and persons acting on their respective behalfs. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital Ltd. announces $1,555,000.00 private placement to advance the company’s medical cannabis initiatives

MONTREAL, Aug. 18, 2017 – LGC Capital Ltd. (TSXV: QBA) (“LGC”) is pleased to announce that it has received conditional approval from the TSX Venture Exchange for a private placement of a maximum of 30,000,000 units at a price of $0.10 per unit, for maximum gross proceeds to LGC of $3.0 million. To date, LGC has received signed subscription agreements and subscription funds for an aggregate amount of $1,555,000, which represents 15,550,000 units. Of that amount, senior management is contributing $300,000. LGC expects that a first closing of the private placement will take place on or about August 24, 2017.

John McMullen, LGC’s CEO, comments: “LGC will use the net proceeds from this private placement to advance the Company’s new initiatives in the global medical cannabis sector and for general working capital purposes. In particular, some of the capital raised will be used to assist with the funding of our new joint venture with AfriAg (Pty) Ltd and our recent investment in the House of Hemp (Pty) Ltd in South Africa. Funding will also be channeled towards seeking new medical cannabis investment opportunities elsewhere in southern Africa and in the Asia Pacific Region.”

Each of the units will be comprised of one common share and one common share purchase warrant; each warrant will entitle its holder to acquire one additional LGC common share at a price of $0.15 for a period of one year from the closing date. In the event that the closing price of LGC’s common shares on the TSX Venture Exchange is at least $0.20 for a period of not less than 20 consecutive trading days, the warrants will expire, at the sole discretion of LGC, on the 30th day after the date on which LGC sends a notice in prescribed form to the holders of the warrants.

The units are being offered to “accredited investors” in some or all of the provinces of Canada and in other jurisdictions, if any, determined by LGC.

At the closing of the private placement, LGC will pay cash commissions to various securities dealers in an amount equal to 8% of the proceeds from the sale of units sold through such dealers. In addition, LGC will issue “broker warrants” to such dealers in an amount equal to 8% of the number of units sold through them. Each of the broker warrants will entitle the holder to purchase one additional LGC common share at a price of $0.10 for a period of six months from the closing date of the private placement.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, and these securities will not be offered or sold in any jurisdiction in which their offer or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws of the United States. Accordingly, these securities will not be offered or sold to persons within the United States unless an exemption from the registration requirements of the 1933 Act and applicable state securities laws is available.

About LGC (http://www.lgc-capital.com)
LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital has now entered into the agricultural space and the medical cannabis sector in southern Africa through its new joint venture with AfriAg and is seeking new investments opportunities in this sector.


For further information please contact:

Canada contact:
John McMullen, Chief Executive Officer
Tel.: (416) 803-0698
Email: John@lgc-capital.com

London contact:
Anthony Samaha, Chief Financial Officer
Tel.: +44 (0) 20 7440 0640

Investor Relations
Dave Burwell
The Howard Group Inc.
Tel.: (403) 221-9015
Toll Free: 1-888-221-0915
Email: dave@howardgroupinc.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital Offers Global Medical Cannabis Industry Year Round Low-Cost Contract Growing And Manufacturing Services From Its High Security And Bonded State-Of-The-Art 40,000 m2 Facilities At Durban’s International Airport In South Africa

MONTREAL and DURBAN, South Africa, Aug. 15, 2017 – LGC Capital Ltd. (TSXV: QBA) (“LGC” or the “Company”) announces that it will now be offering contract medical cannabis growing and processing services to any licenced jurisdiction that can offer medical cannabis.

LGC and its JV Partner AfriAg are fully licenced to grow and transport medical cannabis from South Africa.

The partnership will target international markets looking to save on capital and operating costs and increasing their year round production capacity by growing, refinining and exporting their products from the 40,000 metre2 growing facility at the Dube TradePort Agrizone complex, which is located within the secure and bonded airport precinct of Durban’s King Shaka International Airport in South Africa. The fact the facility is bonded opens up the partnership’s ability to export to the international cannabis marketplace.

LGC and AfriAg (Pty) Ltd can offer year round contract growing and manufacturing services from its current facilities, which feature a purpose built 40,000 m2 temperature-regulated and humidity-controlled greenhouse (all of which is under glass), with refrigerated pack houses, laboratories and offices. This complex is regarded as the most eco-friendly and high-tech agricultural facility in Africa.

“Apart from LGC now looking at new licensed medical cannabis investment opportunities in the Asia-Pacific Region, we are working hard towards significantly expanding our medical cannabis footprint further into the southern African region.” said John McMullen, LGC Capital’s CEO. “At LGC we are excited for this unique opportunity in South Africa as LGC and its partners already have a pre-built glasshouse and greenhouse infrastructure, abundant clean water supply, some of the best heat growing units globally for agriculture, a very competitive labour market and some of the lowest electricity unit costs in the world. LGC and AfriAg can today provide licensed cannabis growers anywhere in the world (in particular the northern hemisphere where costs are high due to severe winter climatic conditions) with a low cost, fully custom, bonded growing and manufacturing platform designed to reduce their capital expenditure, operating costs and increase their speed to not only their domestic licensed markets but to a more global market place through fully bonded and secure facilities.”

LGC, and its JV Partner in the global medical cannabis sector, AfriAg (Pty) Ltd, recently announced on 18 July 2017 that it had signed agreements to acquire a 60% beneficial interest in the House of Hemp (Pty) Ltd, which is South Africa’s one-stop authority on all things hemp and cannabis.

Based in Block “D” of the Dube TradePort’s Agrizone Complex at Durban’s King Shaka International Airport, the facilities feature 40,000 m2 of secure, temperature-regulated and humidity-controlled greenhouse under glass, with refrigerated pack houses, laboratories and offices. This complex is the only licensed indoor growing facility in South Africa and Dube’s AgriZone is regarded as the most eco-friendly and high-tech agricultural facility in Africa and is where House of Hemp is planning to ramp up Research & Development of high-CBD medicinal grade cannabis.

About House of Hemp:

House of Hemp is now a member of the National Hemp Foundation (NHF) and has served as the convener of the NHF’s Human Resource Development Group (in the first phase). House of Hemp is currently the coordinator of the NHF’s Private Sector Working Group.

Licensed in 2010, House of Hemp became the first private company to be awarded an exclusive permit from the Departments of Agriculture and Health to legally cultivate and process hemp in South Africa. Because House of Hemp wanted to reliably expand into the budding industrial market, the company sought an exclusive permit from the Departments of Agriculture and Health to not only import hemp, but also to legally cultivate and process it in South Africa. In 2010, the House of Hemp became the first private company to be awarded such a permit.

As well as supplying hemp fibres and oils, the House of Hemp conducts research and supplies by-products like tow, biomass, dust and seedcake. These have enormous promise, as sustainable replacement materials for a variety of industries globally.

In 2015, House of Hemp partnered with the South African Department of Agriculture & Health. Other key Partnerships established in the same year include the University of the Free State, the Council of Scientific and Industrial Research (CSIR), the Agricultural Research Institute (ARC); the National Agriculture Marketing Council (NAMC); it is owing to these key partnerships that House of Hemp was able to begin conducting research into medical cannabis.

About LGC Capital

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital now plans to enter into the agricultural space in southern Africa through its new joint venture with AfriAg.

About AfriAg

AfriAg (Pty) Ltd is a global agriculture and agri-logistics specialist, and provides crop growing and logistics solutions, food marketing and bespoke distribution services, by road, air and sea, to many major food retailing and wholesale corporations around the world. AfriAg (Pty) Ltd is 40% owned by London listed AfriAg Global PLC.


For further information:
John McMullen, Chief Executive Officer
Tel.: (416) 803-0698
Email: john@lgc-capital.com

Investor Relations Contact:
Dave Burwell
The Howard Group Inc.
Tel.: (403) 221-9015
Toll Free: 1-888-221-0915
Email: dave@howardgroupinc.com

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its Joint Venture with AfriAg, its investment in House of Hemp, and LGC’s operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, the Joint Venture with AfriAg and the investment in House of Hemp could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, changes in government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC, the Joint Venture, and persons acting on their respective behalfs. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.
 
Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital Cannabis Partnership Makes Second Payment Under Agreements To Acquire 60% Interest In South Africa’s House Of Hemp

MONTREAL and DURBAN, South AfricaAug. 1, 2017  – LGC Capital Ltd. (TSXV: QBA) (“LGC” or the “Company”) is pleased to announce that the second payment has been made by the Company and its JV Partner, AfriAg (Pty) Ltd, to the House of Hemp (Pty) Ltd, under the agreement previously announced on July 18, 2017 to acquire a 60% beneficial interest in the House of Hemp.

The House of Hemp is South Africa’s one-stop authority on all things hemp and cannabis. Based in Block D of the Dube TradePort’s Agrizone Complex at Durban’s King Shaka International Airport, which features 40,000 m2 of secure, temperature-regulated and humidity-controlled greenhouse under glass, with refrigerated pack houses, laboratories and offices. This complex regarded as the most eco-friendly and high-tech agricultural facility in Africa and is where House of Hemp is planning to ramp up Research & Development of high-CBD medicinal grade cannabis.

Although medical cannabis is its newest and largest focus, House of Hemp started as an importer and reseller of hemp products, which remains a key element of its business: hempseed oil, hemp protein powder and de-hulled seeds.

House of Hemp is now a member of the National Hemp Foundation (NHF) and has served as the convener of the NHF’s Human Resource Development Group (in the first phase). House of Hemp is currently the coordinator of the NHF’s Private Sector Working Group.

Licensed in 2010, House of Hemp became the first private company to be awarded an exclusive permit from the Departments of Agriculture and Health to legally cultivate and process hemp in South Africa. Because House of Hemp wanted to reliably expand into the budding industrial market, the company sought an exclusive permit from the Departments of Agriculture and Health to not only import hemp, but also to legally cultivate and process it in South Africa. In 2010, the House of Hemp became the first private company to be awarded such a permit.

As well as supplying hemp fibres and oils, the House of Hemp conducts research and supplies by-products like tow, biomass, dust and seedcake. These have enormous promise, as sustainable replacement materials for a variety of industries globally.

In 2015, House of Hemp partnered with the South African Department of Agriculture & Health. Other key Partnerships established in the same year include the University of the Free State, the Council of Scientific and Industrial Research (CSIR), the Agricultural Research Institute (ARC); the National Agriculture Marketing Council (NAMC); it is owing to these key partnerships that House of Hemp was able to begin conducting research into medical cannabis.

About LGC Capital

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital now plans to enter into the agricultural space in southern Africa through its new joint venture with AfriAg.

About AfriAg

AfriAg (Pty) Ltd is a global agriculture and agri-logistics specialist, and provides crop growing and logistics solutions, food marketing and bespoke distribution services, by road, air and sea, to many major food retailing and wholesale corporations around the world. AfriAg (Pty) Ltd is 40% owned by London listed AfriAg Global PLC.


For further information:
John McMullen, Chief Executive Officer
Tel.: (416) 803-0698
Email: john@lgc-capital.com

Investor Relations Contact:
Dave Burwell
The Howard Group Inc.
Tel.: (403) 221-9015
Toll Free: 1-888-221-0915
Email: dave@howardgroupinc.com

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its Joint Venture with AfriAg, its investment in House of Hemp, and LGC’s operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, the Joint Venture with AfriAg and the investment in House of Hemp could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, changes in government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC, the Joint Venture, and persons acting on their respective behalfs. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.
 
Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

LGC Capital Cannabis Partnership Makes First Payment Under Agreements To Acquire 60% Interest In South Africa’s House Of Hemp

MONTREAL and South AfricaJuly 20, 2017 – LGC Capital Ltd. (TSXV: QBA) (“LGC” or the “Company”) is pleased to announce that the first payment has been made by the Company and its JV Partner, AfriAg (Pty) Ltd, to the House of Hemp (Pty) Ltd, under the agreement previously announced on July 18th2017 to acquire a 60% beneficial interest in the House of Hemp.

The House of Hemp is South Africa’s one-stop authority on all things hemp and cannabis.  Based in Block D of the Dube TradePort’s Agrizone Complex at Durban’sKing Shaka International Airport, which features 40,000 m2 of secure, temperature-regulated and humidity-controlled greenhouse under glass, with refrigerated pack houses, laboratories and offices. This complex regarded as the most eco-friendly and high-tech agricultural facility in Africa and is where House of Hemp is planning to ramp up Research & Development of high-CBD medicinal grade cannabis.

Although medical cannabis is its newest and largest focus, House of Hemp started as an importer and reseller of hemp products, which remains a key element of its business: hempseed oil, hemp protein powder and de-hulled seeds.

House of Hemp is now a member of the National Hemp Foundation (NHF) and has served as the convener of the NHF’s Human Resource Development Group (in the first phase). House of Hemp is currently the coordinator of the NHF’s Private Sector Working Group.

Licensed in 2010, House of Hemp became the first private company to be awarded an exclusive permit from the Departments of Agriculture and Health to legally cultivate and process hemp in South Africa. Because House of Hemp wanted to reliably expand into the budding industrial market, the company sought an exclusive permit from the Departments of Agriculture and Health to not only import hemp, but also to legally cultivate and process it in South Africa. In 2010, the House of Hemp became the first private company to be awarded such a permit.

As well as supplying hemp fibres and oils, the House of Hemp conducts research and supplies by-products like tow, biomass, dust and seedcake. These have enormous promise, as sustainable replacement materials for a variety of industries globally.

In 2015, House of Hemp partnered with the South African Department of Agriculture & Health. Other key Partnerships established in the same year include the University of the Free State, the Council of Scientific and Industrial Research (CSIR), the Agricultural Research Institute (ARC); the National Agriculture Marketing Council (NAMC); it is owing to these key partnerships that House of Hemp was able to begin conducting research into medical cannabis.

About LGC Capital

LGC Capital Ltd. is a Canadian incorporated public company listed on the TSX Venture Exchange (TSXV: QBA). LGC Capital’s objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services, many of which have some exposure to high growth Cuban business opportunities and some that have no exposure to Cuba at all. LGC Capital now plans to enter into the agricultural space in southern Africa through its new joint venture with AfriAg.

About AfriAg

AfriAg (Pty) Ltd is a global agriculture and agri-logistics specialist, and provides crop growing and logistics solutions, food marketing and bespoke distribution services, by road, air and sea, to many major food retailing and wholesale corporations around the world. AfriAg (Pty) Ltd is 40% owned by London listed AfriAg Global PLC.


For further information:
John McMullen, Chief Executive Officer
Tel.: (416) 803-0698
Email: john@lgc-capital.com

Investor Relations Contact:
Dave Burwell
The Howard Group Inc.
Tel.: (403) 221-9015
Toll Free: 1-888-221-0915
Email: dave@howardgroupinc.com

 

FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements with respect to LGC Capital Ltd. (“LGC”), its Joint Venture with AfriAg, its investment in House of Hemp, and LGC’s operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as “may”, “will”, “expect”, “estimate”, “anticipate”, “intends”, “believe” or “continue” or the negative thereof or similar variations. The actual results and performance of LGC, the Joint Venture with AfriAg and the investment in House of Hemp could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition, changes in government regulation and the factors described under “Risk Factors and Risk Management” in LGC’s Management’s Discussion and Analysis for the fiscal year ended September 30, 2016, as filed on SEDAR (www.sedar.com). The cautionary statements qualify all forward-looking statements attributable to LGC, the Joint Venture, and persons acting on their respective behalfs. Unless otherwise stated, all forward-looking statements speak only as of the date of this press release and LGC has no obligation to update such statements, except to the extent required by applicable securities laws.
Caution Regarding Press Releases
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.